OSLO, Norway, Feb. 26, 2020 /PRNewswire/ -- Nordic Nanovector
ASA (OSE: NANO) announces that Dr Lars
Nieba has been appointed interim Chief Executive Officer
with immediate effect. Dr Nieba, who is currently the Company's
Chief Technology Officer, replaces Eduardo
Bravo who as of today has left Nordic Nanovector to pursue
other career opportunities.
Dr Nieba joined Nordic Nanovector on 1
December 2019 from Bayer AG where he served in various
operational and strategic roles, Dr Nieba was most recently
responsible for driving Bayer's Chemistry, Manufacturing and
Controls (CMC) strategy for biologicals. He joined Bayer in 2016
following 13 years at F. Hoffmann-La Roche Ltd., where he held
various leadership roles in clinical, operations, supply planning,
biologics technology and technical business development. Prior Dr
Nieba worked for Cytos Biotechnology where he served as Head of
Therapeutic Vaccine Research.
Dr Nieba gained a PhD from the Max-Planck-Institute for
Biochemistry, München and Institute for Biochemistry at the
University of Zürich, and an Executive MBA from the University of
St. Gallen, Switzerland.
Jan H. Egberts, MD, Chairman of Nordic Nanovector, commented:
"The Board is very pleased to appoint Lars Nieba as Nordic
Nanovector's interim CEO. We believe that his significant
operational, development and product supply expertise will be
crucial as we work towards completing the PARADIGME study and
prepare for the planned filing for Betalutin® with the FDA. On
behalf of the Board I would like to thank Eduardo for his
contribution as CEO."
For further information, please contact:
IR enquiries
Jan H. Egberts, Chairman of Nordic Nanovector
Tel: +31-614672518
Email: janegberts@aol.com
Media Enquiries
Mark Swallow/Frazer
Hall/David Dible (Citigate Dewe
Rogerson)
Tel: +44-203-926-8535
Email: nordicnanovector@citigatedewerogerson.com
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative
therapies to patients to address major unmet medical needs and
advance cancer care. The Company aspires to become a leader in the
development of targeted therapies for haematological cancers.
Nordic Nanovector's lead clinical-stage candidate is Betalutin®,
a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an
indication with substantial unmet medical need, representing a
growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector retains
global marketing rights to Betalutin® and intends to actively
participate in the commercialisation of Betalutin® in the US and
other major markets.
Further information can be found
at www.nordicnanovector.com.
Forward-looking statements
This press release contains certain forward-looking
statements. These statements are based on management's current
expectations and are subject to uncertainty and changes in
circumstances, since they relate to events and depend on
circumstances that will occur in the future and which, by their
nature, will have an impact on Nordic Nanovector's business,
financial condition and results of operations. The terms
"anticipates", "assumes", "believes", "can", "could", "estimates",
"expects", "forecasts", "intends", "may", "might", "plans",
"should", "projects", "targets", "will", "would" or, in each case,
their negative, or other variations or comparable terminology are
used to identify forward-looking
CONTACT:
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/nordic-nanovector/r/nordic-nanovector-appoints-dr-lars-nieba-as-interim-chief-executive-officer,c3046650